Try our Advanced Search for more refined results

In Re: Testosterone Replacement Therapy Products Liability Litigation

Track this case

Case Number:

1:14-cv-01748

Court:

Illinois Northern

Nature of Suit:

367(Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability)

Judge:

Honorable Matthew F. Kennelly

Firms

Companies

Government Agencies

Sectors & Industries:

  1. July 17, 2017

    AndroGel Benefits Not Worth Cardiac Risk, Jury Hears

    A man suing AbbVie Inc. over its testosterone replacement therapy, AndroGel, told an Illinois federal jury Monday that the benefits he received from using the gel did not outweigh its risk of heart attack.

  2. July 14, 2017

    AbbVie Needed To Study Heart Impact Of AndroGel, Jury Told

    An expert on pharmaceutical regulation testifying in a trial against AbbVie Inc. over testosterone therapy drug AndroGel told an Illinois federal jury Friday that there was enough evidence of a connection between the drug and heart attacks to warrant further testing and an updated label.

  3. July 13, 2017

    Enough Evidence Tying AndroGel To Heart Attacks, Jury Hears

    There is enough evidence to connect testosterone therapy drugs to an increased risk of heart attack, a cardiologist testifying in a trial against AbbVie Inc. over its AndroGel product told an Illinois federal jury Thursday.

  4. July 10, 2017

    Ex-FDA Chief Tells Jury AndroGel Ads Were Misleading

    The former commissioner of the U.S. Food and Drug Administration told an Illinois federal jury Monday that the ads AbbVie Inc. put out for its product AndroGel misleadingly promoted it for uses beyond what the regulator approved.

  5. July 06, 2017

    AbbVie Tells Jury Studies Don't Tie AndroGel To Heart Attacks

    AbbVie Inc. told an Illinois federal jury Thursday that there are no studies definitively showing a connection between heart attacks and its testosterone product AndroGel, detailing its defense in a lawsuit accusing the drugmaker of downplaying the drug's risks.

  6. July 05, 2017

    AbbVie Sold AndroGel Without Heart Risk Warning, Jury Told

    AbbVie Inc. knew its product AndroGel wasn't approved to treat age-related drops in testosterone, but the company marketed it for that while downplaying an associated risk of heart attacks, attorneys for a man who nearly died after using it told an Illinois federal jury on Wednesday.

  7. June 22, 2017

    2 Bellwethers Selected Against Lilly In Testosterone MDL

    The Illinois federal judge overseeing multidistrict litigation against manufacturers of testosterone replacement therapy drugs on Thursday selected the first two cases that will go to trial against Eli Lilly and Co.

  8. June 08, 2017

    Northwestern Doc Says AbbVie's Androgel Has Heart Risks

    A cardiologist who teaches at Northwestern University was called to the stand Thursday during the fourth day of a bellwether trial against AbbVie Inc. to testify about his belief that testosterone replacement medicines like Androgel increase the risk of heart attacks in older men.

  9. June 06, 2017

    Ex-FDA Head Says AbbVie Promoted Off-Label Androgel Use

    Former U.S. Food and Drug Administration Commissioner David Kessler told jurors Tuesday that he felt AbbVie Inc. had stepped outside the bounds placed on it by the FDA by promoting testosterone replacement therapy drug Androgel for use in aging men without testing the safety of the drug.

  10. June 05, 2017

    AbbVie Confronts 1st Bellwether In Androgel MDL

    AbbVie Inc. is facing its first test in multidistrict litigation accusing the pharmaceutical company and several others of overselling testosterone replacement drugs and not warning of potentially deadly side effects, with a Tennessee man alleging before an Illinois federal jury Monday that AbbVie's Androgel caused his heart attack.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!